» Articles » PMID: 38005888

Human Complement Inhibits Myophages Against

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2023 Nov 25
PMID 38005888
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic bacteriophages (phages) are primarily chosen based on their in vitro bacteriolytic activity. Although anti-phage antibodies are known to inhibit phage infection, the influence of other immune system components is less well known. An important anti-bacterial and anti-viral innate immune system that may interact with phages is the complement system, a cascade of proteases that recognizes and targets invading microorganisms. In this research, we aimed to study the effects of serum components such as complement on the infectivity of different phages targeting . We used a fluorescence-based assay to monitor the killing of by phages of different morphotypes in the presence of human serum. Our results reveal that several myophages are inhibited by serum in a concentration-dependent way, while the activity of four podophages and one siphophage tested in this study is not affected by serum. By using specific nanobodies blocking different components of the complement cascade, we showed that activation of the classical complement pathway is a driver of phage inhibition. To determine the mechanism of inhibition, we produced bioorthogonally labeled fluorescent phages to study their binding by means of microscopy and flow cytometry. We show that phage adsorption is hampered in the presence of active complement. Our results indicate that interactions with complement may affect the in vivo activity of therapeutically administered phages. A better understanding of this phenomenon is essential to optimize the design and application of therapeutic phage cocktails.

Citing Articles

The contribution of neutrophils to bacteriophage clearance and pharmacokinetics in vivo.

Echterhof A, Dharmaraj T, Khosravi A, McBride R, Miesel L, Chia J JCI Insight. 2024; 9(20).

PMID: 39435664 PMC: 11530120. DOI: 10.1172/jci.insight.181309.


The complement system: A key player in the host response to infections.

Jayaraman A, Walachowski S, Bosmann M Eur J Immunol. 2024; 54(11):e2350814.

PMID: 39188171 PMC: 11623386. DOI: 10.1002/eji.202350814.


A Novel Bacteriophage Infecting Multi-Drug- and Extended-Drug-Resistant Strains.

Santamaria-Corral G, Pagan I, Aguilera-Correa J, Esteban J, Garcia-Quintanilla M Antibiotics (Basel). 2024; 13(6).

PMID: 38927189 PMC: 11200629. DOI: 10.3390/antibiotics13060523.

References
1.
Cesta N, Pini M, Mulas T, Materazzi A, Ippolito E, Wagemans J . Application of Phage Therapy in a Case of a Chronic Hip-Prosthetic Joint Infection due to : An Italian Real-Life Experience and Analysis. Open Forum Infect Dis. 2023; 10(2):ofad051. PMC: 9969736. DOI: 10.1093/ofid/ofad051. View

2.
Guerrero-Bustamante C, Dedrick R, Garlena R, Russell D, Hatfull G . Toward a Phage Cocktail for Tuberculosis: Susceptibility and Tuberculocidal Action of Mycobacteriophages against Diverse Mycobacterium tuberculosis Strains. mBio. 2021; 12(3). PMC: 8263002. DOI: 10.1128/mBio.00973-21. View

3.
Molendijk M, Phan M, Bode L, Strepis N, Prasad D, Worp N . Microcalorimetry: A Novel Application to Measure In Vitro Phage Susceptibility of in Human Serum. Viruses. 2023; 15(1). PMC: 9865112. DOI: 10.3390/v15010014. View

4.
Ostrycharz E, Hukowska-Szematowicz B . New Insights into the Role of the Complement System in Human Viral Diseases. Biomolecules. 2022; 12(2). PMC: 8961555. DOI: 10.3390/biom12020226. View

5.
Ricklin D, Lambris J . Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol. 2008; 632:273-92. PMC: 2700864. DOI: 10.1007/978-0-387-78952-1_20. View